Using competence network collaboration and decision-analytic modeling to assess the cost-effectiveness of interferon alpha-2b plus ribavirin as initial treatment of chronic hepatitis C in Germany.
Standard
Using competence network collaboration and decision-analytic modeling to assess the cost-effectiveness of interferon alpha-2b plus ribavirin as initial treatment of chronic hepatitis C in Germany. / Siebert, Uwe; Sroczynski, Gaby; Wasem, Jürgen; Greiner, Wolfgang; Ravens-Sieberer, Ulrike; Aidelsburger, Pamela; Kurth, Bärbel; Bullinger, Monika; J-Matthias, Graf von der Schulenburg; Wong, John; Rossol, Siegbert.
in: EUR J HEALTH ECON, 2005.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Using competence network collaboration and decision-analytic modeling to assess the cost-effectiveness of interferon alpha-2b plus ribavirin as initial treatment of chronic hepatitis C in Germany.
AU - Siebert, Uwe
AU - Sroczynski, Gaby
AU - Wasem, Jürgen
AU - Greiner, Wolfgang
AU - Ravens-Sieberer, Ulrike
AU - Aidelsburger, Pamela
AU - Kurth, Bärbel
AU - Bullinger, Monika
AU - J-Matthias, Graf von der Schulenburg
AU - Wong, John
AU - Rossol, Siegbert
PY - 2005
Y1 - 2005
N2 - The objective of this study was to translate and apply a decision-analytic model for chronic hepatitis C (CHC) to the German health care context using competence network collaboration. The German Hepatitis C Model (GEHMO) competence network used a systematic multistep approach to identify and transfer a high quality Markov model for CHC to the German health care context. GEHMO was used to project lifetime clinical and economic outcomes and to determine the cost-effectiveness of initial antiviral therapy with interferon alpha-2b plus ribavirin from a societal perspective. In 40-year-old patients combination therapy for 24 and 48 weeks increased life expectancy by 1.6 and 2.3 years, respectively, compared with interferon alone for 48 weeks. The discounted incremental cost-utility ratios (ICUR) for combination therapy were 5,500 per quality-adjusted life-year gained (QALY) for 24 weeks and 6,800/QALY for 48 weeks of treatment. ICUR was 9,800/QALY for moving from 24 to 48 weeks of treatment. Combination therapy remained cost-effective in sensitivity analyses. In conclusion, combination therapy with interferon alpha-2b and ribavirin is effective and cost-effective compared with other well-accepted medical treatments. Competence network collaboration and decision modeling provide a useful and efficient approach to combine evidence from international studies with country-specific parameters.
AB - The objective of this study was to translate and apply a decision-analytic model for chronic hepatitis C (CHC) to the German health care context using competence network collaboration. The German Hepatitis C Model (GEHMO) competence network used a systematic multistep approach to identify and transfer a high quality Markov model for CHC to the German health care context. GEHMO was used to project lifetime clinical and economic outcomes and to determine the cost-effectiveness of initial antiviral therapy with interferon alpha-2b plus ribavirin from a societal perspective. In 40-year-old patients combination therapy for 24 and 48 weeks increased life expectancy by 1.6 and 2.3 years, respectively, compared with interferon alone for 48 weeks. The discounted incremental cost-utility ratios (ICUR) for combination therapy were 5,500 per quality-adjusted life-year gained (QALY) for 24 weeks and 6,800/QALY for 48 weeks of treatment. ICUR was 9,800/QALY for moving from 24 to 48 weeks of treatment. Combination therapy remained cost-effective in sensitivity analyses. In conclusion, combination therapy with interferon alpha-2b and ribavirin is effective and cost-effective compared with other well-accepted medical treatments. Competence network collaboration and decision modeling provide a useful and efficient approach to combine evidence from international studies with country-specific parameters.
M3 - SCORING: Zeitschriftenaufsatz
JO - EUR J HEALTH ECON
JF - EUR J HEALTH ECON
SN - 1618-7598
ER -